Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

Launched by ABBOTT · Oct 6, 2014

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female ≥ 18 years to 65 years;
• • Patients suffering from post-cholecystectomy GI-spasms in the last 3 months with symptom onset at least 6 months prior to inclusion and not requiring surgical treatment;
• • Laparoscopic cholecystectomy between 6 months to 5 years before enrollment;
• • Patients having been prescribed Duspatalin® (mebeverine) 200 mg BID (bis in die = twice a day) in accordance with approved local label;
• • Patient's written authorization to provide data for the program
• Exclusion Criteria:
• • General and specific contraindications to Duspatalin® treatment according to the local label;
• • Planned Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or surgical treatment;
• • Being currently treated or having been treated with Duspatalin® within the 6 weeks prior to entering the program;
• • Pregnancy or lactation;
• • Other conditions that make patient participation impossible (by investigator judgment);
• • Previous enrollment in the present program;
• • Treatment with other antispasmodics, pain-medication (Nonsteroidal anti-inflammatory drugs (NSAIDs), tramadol, etc.) within 2 weeks prior to inclusion into the observational study.